Literature DB >> 8762276

[Lipoprotein glomerulopathy: a new French case with recurrence on the transplant].

A Djamali1, J P Cristol, C Turc-Baron, I Beucler, P Baldet, G Mourad.   

Abstract

Lipoprotein glomerulopathy is defined by the presence of lipidic deposits in the capillary lumen giving them a dialted and microaneurysmal aspect and the presence of quantitative and/or qualitative alterations of plasma apolipoprotein E. We describe here the long-term follow-up of a young female patient who presented with corticoresistant nephrotic syndrome in 1979 and progressed to chronic renal failure requiring dialysis in 1990. The three renal biopsies performed during the follow-up showed markedly enlarged capillary loops due to intra-luminal fibrinolipidic material deposition forming true intracapillary thrombi. She received a cadaver renal transplant in 1993. One year after transplantation, nephrotic syndrome reappeared and graft biopsy showed recurrence of the initial glomerular disease on the transplant. The plasma lipid profile showed hypercholesterolemia, hypertriglyceridemia, and elevated plasma ApoE levels with an abnormal Apo E phenotype. Our case report is a new typical case of lipoprotein glomerulopathy with recurrence of the initial disease on the renal allograft.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8762276

Source DB:  PubMed          Journal:  Presse Med        ISSN: 0755-4982            Impact factor:   1.228


  2 in total

1.  Association of apoE gene expression and its gene polymorphism with nephrotic syndrome susceptibility: a meta-analysis of experimental and human studies.

Authors:  Tian-Biao Zhou; Yuan-Han Qin; Hui-Ling Xu
Journal:  Mol Biol Rep       Date:  2012-07-04       Impact factor: 2.316

2.  Identification of apolipoprotein E Guangzhou (arginine 150 proline), a new variant associated with lipoprotein glomerulopathy.

Authors:  Boxun Luo; Fengxian Huang; Qicai Liu; Xiaoyan Li; Wenfang Chen; Shu-Feng Zhou; Xueqing Yu
Journal:  Am J Nephrol       Date:  2007-11-29       Impact factor: 3.754

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.